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BACKGROUND
Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) 
remain elusive. Among them, convalescent plasma administered to hospitalized pa-
tients has been unsuccessful, perhaps because antibodies should be administered 
earlier in the course of illness.
METHODS
We conducted a randomized, double-blind, placebo-controlled trial of convalescent 
plasma with high IgG titers against severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) in older adult patients within 72 hours after the onset of mild Covid-19 
symptoms. The primary end point was severe respiratory disease, defined as a respi-
ratory rate of 30 breaths per minute or more, an oxygen saturation of less than 93% 
while the patient was breathing ambient air, or both. The trial was stopped early 
at 76% of its projected sample size because cases of Covid-19 in the trial region 
decreased considerably and steady enrollment of trial patients became virtually 
impossible.
RESULTS
A total of 160 patients underwent randomization. In the intention-to-treat popula-
tion, severe respiratory disease developed in 13 of 80 patients (16%) who received 
convalescent plasma and 25 of 80 patients (31%) who received placebo (relative risk, 
0.52; 95% confidence interval [CI], 0.29 to 0.94; P = 0.03), with a relative risk reduc-
tion of 48%. A modified intention-to-treat analysis that excluded 6 patients who had 
a primary end-point event before infusion of convalescent plasma or placebo showed 
a larger effect size (relative risk, 0.40; 95% CI, 0.20 to 0.81). No solicited adverse 
events were observed.
CONCLUSIONS
Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly 
ill infected older adults reduced the progression of Covid-19. (Funded by the Bill and 
Melinda Gates Foundation and the Fundación INFANT Pandemic Fund; Dirección de 
Sangre y Medicina Transfusional del Ministerio de Salud number, PAEPCC19, Plata-
forma de Registro Informatizado de Investigaciones en Salud number, 1421, and 
ClinicalTrials.gov number, NCT04479163.)
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (Covid-19), 
causes a particularly severe illness in older adults. 
The percentage of these patients who are hospi-
talized is high, and most deaths from Covid-19 
worldwide occur in this age group.1,2 Various 
coexisting conditions adversely affect the prog-
nosis in patients with Covid-19, regardless of age. 
These conditions include hypertension, diabetes, 
cardiovascular disease, obesity, chronic renal fail-
ure, and chronic obstructive pulmonary disease 
(COPD).1,2
Treatments for Covid-19 in the early stages of 
the disease remain elusive. Few strategies provide 
benefit, several have failed, and others are being 
evaluated.3-12 Among the strategies under investiga-
tion is the infusion of specific antibodies that are 
present in the plasma of convalescent patients.7-12 
Plasma infusions have not been commonly asso-
ciated with adverse events13 and have been asso-
ciated with improved outcomes in patients who 
have had other diseases.14-16 However, antibodies 
in plasma must be administered soon after infec-
tion in order to be effective.14-16
In hospitalized patients with Covid-19, the 
infusion of convalescent plasma against SARS-
CoV-2 late in the course of illness has not shown 
clear benefits and, consequently, the most appro-
priate antibody concentrations for effective treat-
ment are unclear.7-12 We evaluated whether con-
valescent plasma with high SARS-CoV-2 antibody 
titers, administered within 72 hours after the 
onset of mild symptoms, would be efficacious in 
preventing progression to severe disease in older 
adult patients with Covid-19.
Me thods
Trial Design and Oversight
We conducted a randomized, double-blind, pla-
cebo-controlled trial between June 4, 2020, and 
October 25, 2020 (when the last patient com-
pleted follow-up), at clinical sites and geriatric 
units in Argentina. The trial was approved by the 
institutional review boards of the participating 
institutions and the state of Buenos Aires and 
was supervised by an independent data and safety 
monitoring board. The authors who designed the 
trial and wrote the manuscript are listed in Table 
S15 in the Supplementary Appendix, available with 
the full text of this article at NEJM.org. All the 
authors compiled the data and vouch for the ac-
curacy and completeness of the data and the ad-
herence of the trial to the protocol, available at 
NEJM.org. Three of the authors analyzed the data. 
The last author wrote the first draft of the manu-
script. No one who is not an author contributed 
to the writing of the manuscript. No confidenti-
ality agreements related to the data are in place 
between the sponsors and the authors or their in-
stitutions.
Trial Patients
Patients who were 75 years of age or older, ir-
respective of current coexisting conditions, or 
between 65 and 74 years of age with at least one 
coexisting condition were identified and assessed 
for eligibility. Coexisting conditions, which are 
defined in Table S1, included hypertension or 
diabetes for which the patient was currently re-
ceiving pharmacologic treatment, obesity, chronic 
renal failure, cardiovascular disease, and COPD. 
At the time of screening for SARS-CoV-2 by re-
verse-transcriptase–polymerase-chain-reaction 
(RT-PCR) assay, eligible patients had had at least 
one of each sign or symptom in the following two 
categories for less than 48 hours: a temperature 
of at least 37.5°C, unexplained sweating, or chills; 
and dry cough, dyspnea, fatigue, myalgia, an-
orexia, sore throat, dysgeusia, anosmia, or rhinor-
rhea. Exclusion criteria included severe respiratory 
disease (the primary end point), any disease listed 
in Table S5, or both.
Patients who provided consent to undergo 
screening received home visits, and samples of 
nasopharyngeal and oropharyngeal secretions 
were obtained for testing with an RT-PCR assay 
(iAMP COVID-19, Atila BioSystems) to detect 
SARS-CoV-2. Patients with detectable SARS-CoV-2 
RNA were transported to trial hospitals and in-
vited to sign the informed-consent form. After 
July 22, 2020, legal guardians provided consent 
for patients who had cognitive impairment. 
Starting on July 27, 2020, since several geriatric 
institutions with SARS-CoV-2 outbreaks were 
transformed into low-complexity inpatient units 
for mildly ill residents infected with SARS-CoV-2, 
we screened and invited residents who met the 
trial criteria to participate in the trial on-site.
Randomization and Intervention
Eligible patients who provided written informed 
consent were randomly assigned to receive either 
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250 ml of convalescent plasma with an IgG titer 
greater than 1:1000 against SARS-CoV-2 spike (S) 
protein (COVIDAR IgG, Instituto Leloir, Argen-
tina) or 250 ml of placebo (0.9% normal saline). 
The convalescent plasma was arbitrarily defined 
as “high-titer” and included antibody concentra-
tions in the upper 28th percentile. A computer-
generated randomization sequence with a bal-
anced permuted block design (block size 2) was 
prepared at the data center.
Convalescent plasma or placebo was adminis-
tered less than 72 hours after the onset of symp-
toms, and the infusions were given over a period 
of 1.5 to 2.0 hours. Both the convalescent plasma 
and placebo were concealed with opaque bags 
and tape to cover the infusion catheter. Patients 
were monitored for adverse events until 12 hours 
after the intervention.
A total of 479 potential plasma donors who 
had had SARS-CoV-2 infection for a minimum 
of 10 days and who had been asymptomatic for 
3 days or longer and had two negative RT-PCR 
tests17 were identified through hospital lists and 
an online campaign. Potential donors who pro-
vided written informed consent were visited at 
home and screened for SARS-CoV-2 S IgG at a 
titer greater than 1:1000 in serum. Each of the 
135 candidates (28%) with adequate titers donated 
750 ml of plasma (see Fig. S6).
Clinical and Laboratory Monitoring
A total of 24 hours after the end of the infusion, 
a sample of venous blood (5 ml) was obtained from 
the patients. Serum samples were preserved at 
−20°C until completion of the trial. We assayed 
anti–S IgG SARS-CoV-2 using the COVIDAR IgG 
test. In addition, we assayed samples using the 
SARS-CoV-2 Spike S1-RBD IgG enzyme-linked im-
munosorbent assay detection kit (GenScript) and 
the SARS-CoV-2 surrogate virus neutralization 
test kit (GenScript).
The patients’ clinical status was monitored 
daily by trial physicians until day 15 to assess for 
primary end-point events that occurred in the 
hospital, in participating geriatric institutions, 
or at home if the patients had been discharged 
(Figs. S7 and S8). Patients who had persistent 
symptoms for which medical care was warranted 
were followed until the resolution of symptoms 
or for a maximum of 25 days to assess for sec-
ondary end-point events. The trial physicians used 
predesigned questionnaires to collect clinical in-
formation. None of the patients received any 
experimental therapy for Covid-19 besides con-
valescent plasma. Data were recorded on paper 
forms and then double-entered into an electronic 
database.
Trial End Points
The primary end point of the trial was the devel-
opment of severe respiratory disease, defined as 
a respiratory rate of 30 breaths per minute or 
more, an oxygen saturation of less than 93% 
while the patient was breathing ambient air, or 
both. Patients were assessed for this end-point 
event between 12 hours after the infusion of con-
valescent plasma or placebo and day 15 of trial 
participation.
Prespecified secondary clinical end points were 
life-threatening respiratory disease (defined as 
oxygen supplementation at a fraction of inspired 
oxygen [Fio2] of 100%, noninvasive or invasive 
ventilation, admission to an intensive care unit, 
or any combination of these), critical systemic ill-
ness (respiratory failure with a ratio of the partial 
pressure of oxygen to Fio2 ≤200 mm Hg, shock, 
multiple organ dysfunction syndrome, or any com-
bination of these), and death associated with 
Covid-19. Patients in whom the illness had not 
resolved were assessed for these end-point events 
until day 25 of trial participation. On July 22, 2020, 
we amended the protocol to include a fourth sec-
ondary end point that included any of the three 
secondary end points described above, alone or in 
combination.
Early Trial Termination
The trial was initiated when the number of cases 
of Covid-19 in Buenos Aires was high. However, 
as the number of cases decreased, it became clear 
that it would take approximately 5 months to reach 
the enrollment goal. Consequently, after discus-
sions with the data and safety monitoring board 
and enrollment of 76% of the target population, 
we decided that it would be logistically impos-
sible and ethically questionable, given the daily 
cost of the pandemic in lives and illness, to con-
tinue the trial, and we stopped to examine the 
results.
Statistical Analysis
Given the complexity of implementing this inter-
vention, the minimal clinically important differ-
ence was set at a 40% relative reduction for an 
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expected 50% of the patients in the placebo 
group and 30% of the patients in the convales-
cent plasma group who would have a primary 
end-point event. We estimated that a total sam-
ple size of 210 patients (105 per trial group) 
would provide the trial with 80% power to detect 
a between-group difference, at a significance level 
of α = 0.05. We used a two-sided z-test of propor-
tions with continuity correction and one planned 
interim analysis with the O’Brien–Fleming spend-
ing function to determine the test boundaries.
In the intention-to-treat analysis, the end 
points were assessed from the time of random-
ization. Continuous variables are presented as 
means and standard deviations or medians and 
interquartile ranges, as appropriate, and categori-
cal variables are presented as percentages.
In the primary analysis strategy, we used the 
Kaplan–Meier product limit estimates to compare 
the time to reach the primary end point in the 
trial groups. An estimate of the relative risk 
and 95% confidence interval was also reported. 
A modified intention-to-treat analysis excluded 
patients who became ineligible between random-
ization and the administration of convalescent 
plasma or placebo.
The protocol prespecified an evaluation of IgG 
protection correlates and a subgroup analysis that 
was suggested by the data and safety monitoring 
board and approved by the institutional review 
boards on November 2, 2020. This analysis in-
cluded an evaluation of end-point events in patients 
who were 75 years of age or older, irrespective of 
coexisting conditions, and in those between 65 




A total of 165 patients presented with symptoms 
that met the eligibility criteria and tested posi-
tive for SARS-CoV-2 RNA (Fig. S1). Four of these 
patients became ineligible before enrollment, and 
one did not provide consent to participate in the 
trial. Therefore, 160 patients with SARS-CoV-2 in-
fection underwent randomization; 80 were as-
signed to receive convalescent plasma and 80 were 
assigned to receive placebo. Five of 160 patients 
(3%; 3 patients who were assigned to receive con-
valescent plasma and 2 who were assigned to re-
ceive placebo) received convalescent plasma or 
placebo after they had a primary end-point event. 
Hypoxemia developed before the infusion in an 
additional patient who had been assigned to re-
ceive convalescent plasma, and that patient did 
not receive convalescent plasma but was included 
in the analysis.
A total of 160 patients were included in the 
intention-to-treat analysis. One patient voluntarily 
left the trial on day 9 of follow-up. After day 15, 
a total of 38 of 160 patients (24%) continued to 
have Covid-19 symptoms for which hospitalization 
was warranted, and they were followed for 16 to 
25 days, until recovery or death. By day 25 of 
follow-up, only 2 patients were receiving oxygen 
support. Both recovered by day 27.
The mean (±SD) age of the patients was 
77.2±8.6 years, and 100 patients (62%) were wom-
en (Table 1). A total of 72 patients (45%) were 
65 to 74 years of age and 88 (55%) were 75 years 
of age or older. There were no clinically signifi-
cant imbalances in baseline characteristics be-
tween the convalescent plasma and placebo groups. 
Most patients had prespecified coexisting condi-
tions at enrollment (Table 1). The administration 
of convalescent plasma was not associated with 
any solicited adverse events (Table S6).
Primary End Point
In the intention-to-treat population, severe respi-
ratory disease developed in 13 of 80 patients (16%) 
who received convalescent plasma and in 25 of 
80 patients (31%) who received placebo (relative 
risk, 0.52; 95% confidence interval [CI], 0.29 to 
0.94; P = 0.03) (Table 2). As shown in Figure 1, in 
the time-to-event analysis, the median time to the 
development of severe respiratory disease in the 
convalescent plasma group (15 days; interquar-
tile range, 15 to 15) was longer than that in the 
placebo group (15 days; interquartile range, 9 to 
15) (P = 0.03). The relative risk reduction with 
convalescent plasma was 48%, and the number 
needed to treat to avert an episode of severe re-
spiratory disease was 7 (95% CI, 4 to 50).
Four patients in the convalescent plasma group 
and 2 patients in the placebo group became in-
eligible because they had a primary end-point 
event before they received convalescent plasma 
or placebo (one of them, who was assigned to 
receive convalescent plasma, did not receive a 
transfusion). A modified intention-to-treat pop-
ulation that excluded these patients showed a 
larger intervention effect size; severe respiratory 
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disease developed in 9 of 76 patients (12%) in 
the convalescent plasma group and 23 of 78 pa-
tients (29%) in the placebo group (relative risk, 
0.40; 95% CI, 0.20 to 0.81). In the modified in-
tention-to-treat population, patients in the con-
valescent plasma group also had a longer time to 
the development of severe respiratory disease than 
those in the placebo group (see Fig. S2).







Age — yr 76.4±8.7 77.9±8.4
Age category — no./total no. (%)
65–74 yr 40/80 (50) 32/80 (40)
≥75 yr 40/80 (50) 48/80 (60)
Sex — no./total no. (%)
Female 54/80 (68) 46/80 (58)
Male 26/80 (32) 34/80 (42)
Vital signs
Axillary temperature — °C 36.5±0.7 36.8±0.8
Heart rate — beats/min 79.8±13.4 78.6±14.1
Blood pressure — mm Hg
Systolic 124.8±15.6 125.4±15.3
Diastolic 75.1±11.2 75±10.9
Respiratory rate — breaths/min 17±2.8 17.3±3.0
Oxygen saturation while breathing ambient air — % 96.1±1.6 96.1±1.7
Time since onset of symptoms — hr 39.6±13.9 38.3±14.3
Primary coexisting conditions — no./total no. (%)
Hypertension for which treatment was being received 62/80 (78) 52/80 (65)
Diabetes for which treatment was being received 23/80 (29) 13/79 (16)
Obesity 4/80 (5) 8/79 (10)
COPD for which treatment was being received 2/80 (2) 5/79 (6)
Cardiovascular disease 14/80 (18) 7/79 (9)
Chronic renal failure 1/80 (1) 3/79 (4)
At least one primary coexisting condition 69/80 (86) 62/80 (78)
Secondary coexisting conditions — no./total no. (%)
Asthma or other respiratory disease 3/80 (4) 3/80 (4)
Noncirrhotic liver disease 0/80 0/80
Cancer in remission 4/80 (5) 2/80 (2)
Neurologic disease 11/80 (14) 9/80 (11)
History of smoking 13/80 (16) 10/80 (12)
Use of medication
Regular use 76/80 (95) 73/80 (91)
Use in past 15 days 71/80 (89) 64/80 (80)
SARS-CoV-2 cycle-threshold value — cycles 16.4±7.4 16.0±7.9
*  Plus–minus values are means ±SD. COPD denotes chronic obstructive pulmonary disease, and SARS-CoV-2 severe 
acute respiratory syndrome coronavirus 2.
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Secondary End Points
Secondary end-point results are provided in Ta-
ble 2. Four convalescent plasma recipients (5%) 
and 10 placebo recipients (12%) had life-threaten-
ing respiratory disease, and 5 (6%) and 6 (8%), 
respectively, had a critical systemic illness. Two 
patients in the convalescent plasma group and 
4 patients in the placebo group died. A combined 
secondary end-point event (life-threatening respi-
ratory disease, critical systemic illness, and death, 
or any of these outcomes) occurred in 7 patients 
(9%) who received convalescent plasma and 12 
patients (15%) who received placebo. Secondary 
end-point results in the modified intention-to-
treat analysis are presented in Table S10.
Antibody Titers
The distribution of anti–SARS-CoV-2 serum S IgG 
titers 24 hours after infusion differed significantly 
in the two groups, with higher concentrations in 
patients in the convalescent plasma group (me-
dian log anti–SARS-CoV-2 S IgG titer, 5.7; inter-
quartile range, 4.9 to 6.3) than in those in the 
placebo group (median log anti–SARS-CoV-2 S 
IgG titer, 3.9; interquartile range, 3.9 to 4.7) 









Primary end point: severe respiratory disease 13/80 (16) 25/80 (31) 0.52 (0.29–0.94)
Secondary end points
Life-threatening respiratory disease 4/80 (5) 10/80 (12) 0.40 (0.13–1.22)
Oxygen supplementation at an Fio2 of 100% 4/80 (5) 6/80 (8) 0.67 (0.20–2.27)
Noninvasive ventilation 1/80 (1) 6/80 (8) 0.17 (0.02–1.35)
Admission to intensive care unit 2/80 (2) 6/80 (8) 0.33 (0.07–1.60)
Mechanical ventilation 2/80 (2) 4/80 (5) 0.50 (0.09–2.65)
Critical systemic illness 5/80 (6) 6/80 (8) 0.83 (0.27–2.62)
Acute respiratory failure 2/80 (2) 5/80 (6) 0.40 (0.08–2.00)
Shock 2/80 (2) 1/80 (1) 2.00 (0.19–21.6)
Multiple organ dysfunction syndrome 3/80 (4) 5/80 (6) 0.60 (0.15–2.43)
Death from Covid-19 2/80 (2) 4/80 (5) 0.50 (0.09–2.65)
Life-threatening respiratory disease, critical systemic 
illness, or death, alone or in combination
7/80 (9) 12/80 (15) 0.58 (0.24–1.41)
*  CI denotes confidence interval, and Fio2 fraction of inspired oxygen.
Figure 1. Time to the Development of Severe Respiratory Disease Due to 
Coronavirus Disease 2019, According to Trial Group in the Intention-to-
Treat Analysis.
Shown are Kaplan–Meier estimates of the time from the intervention  
(administration of convalescent plasma or placebo) to the development of 
severe respiratory disease. The tick marks on the curves represent the in-
terquartile range in the Kaplan–Meier time-to-event analysis in the conva-
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(Fig. 2). A comparison between severe and mild 
cases of illness showed no IgG correlate of pro-
tection for antibodies against SARS-CoV-2 in the 
serum samples of convalescent plasma recipients 
(Fig. S5B).
Conversely, a dose-dependent effect was ob-
served for SARS-CoV-2 S IgG titers in plasma bags 
(Table 3). Donor titers selected on the basis of a 
median titer of 1:3200 showed a relative risk re-
duction of 73.3%, with a number needed to treat 
of 4 (range, 3 to 11) to avoid a worsening of 
Covid-19 in recipients of antibody concentrations 
above the median concentration (Table 3). The 
SARS-CoV-2 S IgG results were replicated with 
the use of a different SARS-CoV-2 spike S1-RBD 
IgG commercial assay; this assay provides a po-
tential alternative tool for donor selection (r = 0.7; 
95% CI, 0.6 to 0.8) (see Fig. S3).
 Discussion
We report the use of convalescent plasma in older 
adult patients early in the course of Covid-19. 
The administration of convalescent plasma with 
high titers of antibodies against SARS-CoV-2 to 
infected patients within 72 hours after the onset 
of symptoms reduced the risk of progression to 
severe respiratory disease by 48%. Although our 
trial lacked the statistical power to discern long-
term outcomes, the convalescent plasma group 
appeared to have better outcomes than the pla-
cebo group with respect to all secondary end 
points. Our findings underscore the need to re-
turn to the classic approach of treating acute 
viral infections early, and they define IgG targets 
that facilitate donor selection.
Our trial has fundamental differences in de-
sign from previous randomized trials of conva-
lescent plasma therapy in patients with Covid-19 
(see Table S14).7-11 For example, we focused on 
older adults because they are most affected by the 
Covid-19 pandemic.1,2 Previous trials involved 
adults who were 18 years of age or older.7-11 In 
addition, we aimed to stop disease progression 
early and at a mild stage. Our primary end point 
was an enrollment criterion in previous studies. 
Consequently, our patients had had symptoms 
for less than 3 days at enrollment, whereas the 
median duration of symptoms ranged from 8 to 
30 days in other trials.7-11
Studies have suggested that antibody interven-
tions against Covid-19 work better when admin-
istered early in the course of the illness. In one 
study involving patients in Houston, mortality 
decreased only among patients who received con-
valescent plasma within 72 hours after admis-
sion,8 and in a large U.S. multicenter study, mor-
tality at 7 days was lower among hospitalized 
Figure 2. SARS-CoV-2 Serum Titers, According to Trial Group.
Shown are IgG antibody titers against SARS-CoV-2 spike (S) protein in the 
convalescent plasma and placebo groups 24 hours after infusion. The hori-
zontal bars indicate medians, and the shaded gray areas interquartile rang-






























 Table 3. Primary End Point, According to Donor SARS-CoV-2 S IgG Titer.
Patient Group






no./total no. (%) percent
Placebo group 25/80 (31) 1.00
Recipient of SARS-CoV-2 S IgG in donor plasma*
At a titer at or above median concentration 3/36 (8) 0.27 (0.08–0.68) 73.3
At a titer below median concentration 9/42 (21) 0.69 (0.34–1.31) 31.4
*  The median concentration is a SARS-CoV-2 S IgG titer of 1:3200.
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patients who received transfusions within 72 
hours after diagnosis than among those who 
received transfusions later.12 Recently, on the ba-
sis of clinical benefits that were prespecified in 
the secondary end points of the Blocking Viral 
Attachment and Cell Entry with SARS-CoV-2 Neu-
tralizing Antibodies (BLAZE-1) trial, the Food and 
Drug Administration granted emergency use 
authorization for monoclonal antibodies to treat 
outpatients with mild-to-moderate Covid-19.18,19 
Access to convalescent plasma can be rapid in 
many low- and middle-income countries, and at 
a per-patient cost of $186.25 (U.S. dollars) for 
plasma infusion in Buenos Aires (Table S13), it 
is a potentially inexpensive alternative to mono-
clonal antibodies. The early administration of 
convalescent plasma in our small randomized 
clinical trial, which had a wide 95% confidence 
interval for the primary end point, was not as-
sociated with any serious side effects.
In order to provide convalescent plasma of all 
blood types to 15 institutions, two infusion teams 
with persons who were aware of the trial-group 
assignments drove from a central hemotherapy 
station where the convalescent plasma was stored 
to all the trial hospitals after randomization. The 
trial region was more than 100 square miles, 
and security challenges precluded access to sev-
eral hospitals after 8 p.m. Consequently, six pa-
tients had a primary end-point event before they 
received convalescent plasma or placebo. The 
exclusion of these patients in the modified in-
tention-to-treat analysis increased the efficacy to 
60%. Again, this finding suggests that early in-
tervention is critical for efficacy.
Our trial showed a dose-dependent IgG effect 
in convalescent plasma infusions. Plasma with 
IgG titers of 1:3200 or higher reduced the risk of 
severe respiratory disease by 73%; this explor-
atory result directly implicates antibodies as the 
active therapeutic ingredient in convalescent plas-
ma. “Super donors” with IgG titers of 1:12,800 or 
higher and perhaps immunized persons in the 
future could contribute to build a therapeutic 
arsenal. Among the plasma donors in our trial, 
71% of those with titers of 1:3200 or higher had 
been hospitalized. Since high IgG titers can be 
maintained for months, hospitalized patients with 
high titers should be identified for future plasma 
donations.20
In our randomized, controlled trial, the ad-
ministration of high-titer convalescent plasma 
against SARS-CoV-2 to infected older adults with-
in 72 hours after the onset of mild symptoms 
reduced the progression of Covid-19 to severe 
illness. This simple and inexpensive intervention 
can reduce demands on the health care system 
and may save lives. Early infusions of convales-
cent plasma can provide a bridge to recovery for 
at-risk patients until vaccines become widely 
available.
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